Bio-Techne Corp at JPMorgan Healthcare Conference Summary

The following is excerpted from the question-and-answer section of the transcript.

Question: Casey Woodring - J.P. Morgan - Analyst : Great. That was a that was a very helpful overview. So maybe just to start on the macro here. BioPharma demand has been choppy for the industry over the last year or so. What's your outlook for the remainder of fiscal '25 for that end market?

Question: Casey Woodring - J.P. Morgan - Analyst : That's helpful. There have been some recent concerns over the potential impact of the new administration life science tools including NIH budgets and the potential impact on tariffs. How do you view Techne the potential impact there on your business?

Question: Casey Woodring - J.P. Morgan - Analyst : So Techne has been one of the more vocal companies on the potential impact of Chinese stimulus on your business starting in the calendar year '25. So any updates you can share there.

Question: Casey Woodring - J.P. Morgan - Analyst : Got it. I guess taking all those macro factors we just talked about into account any updates on the fiscal '25 outlook you provided during the 1Q earning call.

Question: Casey Woodring - J.P. Morgan - Analyst : Okay. Shifting to some questions on your portfolio. Within cell and gene therapy, GMP proteins has been really strong for you guys increasing over 60% last quarter. What drove the strength? And what is the realistic growth rate for that business moving forward?

Question: Casey Woodring - J.P. Morgan - Analyst : Got it. One of the other future drivers of your cell and gene therapy business is Wilson Wolf, you mentioned it during the presentation. You own currently 20% of that company. How does this business fit strategically with your current offering? And any updates there on that business? REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies.

Question: Casey Woodring - J.P. Morgan - Analyst : Okay. Turning to your insurance business here, just as an overview, what are the primary platforms in that portfolio? How is your current offering differentiated first competitors? And maybe just walk through demand trends currently?

Question: Casey Woodring - J.P. Morgan - Analyst : Got it. I wanted to touch on M&A here. So Techne has historically been a very acquisitive company, completed almost 20 acquisitions since 2013. What's your appetite for potential additional M&A? And does the pending Wilson Wolf acquisition impact your ability to do deals in the near term? REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies.

Question: Casey Woodring - J.P. Morgan - Analyst : Got it. That's helpful. We have a couple of minutes left here. Just finally, Kim, you've been CEO for now about a year. What have been some of the key changes you've implemented since taking over the reins and what are the key initiatives over the next 12 to 18 months in your view?

Question: Casey Woodring - J.P. Morgan - Analyst : Got. It looks like we have time for one more question. Just we didn't get to it, but on spatial, that's been a hot area. Some companies have had mixed results in that space. Can you just talk about your current offering and how you've been able to outpace the competition there? REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies.

Question: Casey Woodring - J.P. Morgan - Analyst : Got it. Well, it looks like we'll have to leave it there. Thank you, guys, for joining us today. Thank you, everybody, for coming. Have a great rest of your conference.